• SENSEX
    NIFTY 50
Market

Top Brokerage calls for July 30: Morgan Stanley 'equal-weight' on Dr Reddy's; CLSA bearish on Kansai Nerolac

Updated : 2019-07-30 08:18:42

Indian benchmark indices are likely to start on a positive note on Tuesday, tracking Asian stocks which climbed up as investors gear up for an expected US interest rate cut this week. Among brokerages, BofAML upgraded Bharti Airtel to 'buy' while CLSA maintained 'sell rating on Kansai Nerolac. Here are the top brokerage calls for Tuesday:

<strong>CLSA on Kansai Nerolac:</strong> The brokerage maintained a 'sell' rating but raised the target price to Rs 390 per share from Rs 385 earlier. Good start to FY20 with positive earnings growth, it said but added it is concerned about the company's exposure to auto OEMs.
CLSA on Kansai Nerolac: The brokerage maintained a 'sell' rating but raised the target price to Rs 390 per share from Rs 385 earlier. Good start to FY20 with positive earnings growth, it said but added it is concerned about the company's exposure to auto OEMs.
<strong>BofAML on Bharti Airtel:</strong> The brokerage upgraded the stock to 'buy' and raised the target to Rs 400 from Rs 300 earlier. Post rights issue/Africa IPO, the company's balance sheet has strengthened.
BofAML on Bharti Airtel: The brokerage upgraded the stock to 'buy' and raised the target to Rs 400 from Rs 300 earlier. Post rights issue/Africa IPO, the company's balance sheet has strengthened.
<strong>Credit Suisse on Dr Reddy's:</strong> The brokerage has an 'underperform' rating on the stock with a target of Rs 2,415 per share. Reported EBITDA benefitted from lower R&D but was offset by low active pharmaceutical ingredients (API) margin, CS said.
Credit Suisse on Dr Reddy's: The brokerage has an 'underperform' rating on the stock with a target of Rs 2,415 per share. Reported EBITDA benefitted from lower R&D but was offset by low active pharmaceutical ingredients (API) margin, CS said.
Morgan Stanley on Dr Reddy's: The brokerage has an 'equal-weight' call on the stock with a target of Rs 2,804 per share. The company continues to focus on six businesses — US, China, Russia, India, API, and Global Hospital, it added.
Morgan Stanley on Dr Reddy's: The brokerage has an 'equal-weight' call on the stock with a target of Rs 2,804 per share. The company continues to focus on six businesses — US, China, Russia, India, API, and Global Hospital, it added.
<strong>CLSA on Dr Reddy's:</strong> The brokerage has a 'buy' call on the stock with a target of Rs 3,330 per share. The company is on track to deliver on its realigned strategy, it added.
CLSA on Dr Reddy's: The brokerage has a 'buy' call on the stock with a target of Rs 3,330 per share. The company is on track to deliver on its realigned strategy, it added.
<strong>Jefferies on Gas Companies</strong>: The brokerage upgraded Mahanagar Gas to 'buy' from 'underperform' and downgraded Gujarat Gas to 'hold'. The brokerage also downgraded Indraprastha Gas to 'hold'.
Jefferies on Gas Companies: The brokerage upgraded Mahanagar Gas to 'buy' from 'underperform' and downgraded Gujarat Gas to 'hold'. The brokerage also downgraded Indraprastha Gas to 'hold'.
<strong>CLSA on Supreme Industries:</strong> The brokerage retained a 'buy' call on the stock but cut target price to Rs 1,274 per share from Rs 1,320 earlier. Packaging margin remains weak, but piping volumes are strong, the brokerage said.
CLSA on Supreme Industries: The brokerage retained a 'buy' call on the stock but cut target price to Rs 1,274 per share from Rs 1,320 earlier. Packaging margin remains weak, but piping volumes are strong, the brokerage said.
Live TV

Ask Our Experts CNBC TV18